Energy -
Oil & Gas Midstream - NYSE - BM
$ 17.7264
1.41 %
$ 3.95 B
Market Cap
7.21
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Frontline Ltd.
| Current Assets | 728 M |
| Cash & Short-Term Investments | 316 M |
| Receivables | 144 M |
| Other Current Assets | 268 M |
| Non-Current Assets | 5.15 B |
| Long-Term Investments | 51.5 M |
| PP&E | 4.64 B |
| Other Non-Current Assets | 468 M |
| Current Liabilities | 409 M |
| Accounts Payable | 7.8 M |
| Short-Term Debt | 263 M |
| Other Current Liabilities | 138 M |
| Non-Current Liabilities | 3.2 B |
| Long-Term Debt | 3.2 B |
| Other Non-Current Liabilities | 472 K |
EFFICIENCY
Earnings Waterfall
Frontline Ltd.
| Revenue | 1.8 B |
| Cost Of Revenue | 1.03 B |
| Gross Profit | 776 M |
| Operating Expenses | 29.4 M |
| Operating Income | 747 M |
| Other Expenses | 90.3 M |
| Net Income | 656 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Frontline Ltd.
| Net Income | 656 M |
| Depreciation & Amortization | 231 M |
| Capital Expenditures | -1.63 B |
| Stock-Based Compensation | 10.7 M |
| Change in Working Capital | -8.51 M |
| Others | -39.5 M |
| Free Cash Flow | -775 M |
Wall Street Analysts Price Targets
Frontline Ltd.
Wall Street analysts predict an average 1-year price target for FRO of $28.3 , with forecasts ranging from
a
low of
$25 to a high of $30 .
FRO Lowest Price Target
Wall Street Target
25 USD
41.03%
FRO Average Price Target
Wall Street Target
28.3 USD
59.84%
FRO Highest Price Target
Wall Street Target
30 USD
69.24%
4. DIVIDEND
ANALYSIS
2.71%
DIVIDEND YIELD
0.34 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Frontline Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline triple drug combination (triplet) therapy for patients newly diagnosed with acute myeloid leukemia, or AML. Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated.
globenewswire.com
- 3 weeks ago
New Body Camera by Motorola Solutions Boosts Safety for Frontline Workers
CHICAGO--(BUSINESS WIRE)--Motorola Solutions (NYSE: MSI) today unveiled the V200, a body camera designed specifically to help protect frontline workers in stores, hospitals, hotels, schools and stadiums. Workers in these settings regularly face safety concerns – from unwelcome behavior to theft and medical emergencies – and the V200, with its GoLive Audio safety feature, offers a direct connection to help. The V200 body camera is a discreet, lightweight addition to a worker's uniform. The recor.
businesswire.com
- 3 weeks ago
4 Of 35 Safe-Buy Dividend Power Dogs In January
Four low-priced Dividend Power stocks, Golden Ocean, Invesco Mortgage, ARMOUR Residential, and FutureFuel, offer safer dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for top Dividend Power stocks, with an average net gain of 79.97% on $10k invested in the top ten.
seekingalpha.com
- 3 weeks ago
Verizon Frontline showcases advanced communications solutions at EDGE25
The EDGE25 keynote will be delivered by Verizon Frontline and the U.S. Secret Service The EDGE25 keynote will be delivered by Verizon Frontline and the U.S. Secret Service
globenewswire.com
- 4 weeks ago
Is the Options Market Predicting a Spike in Frontline (FRO) Stock?
Investors need to pay close attention to Frontline (FRO) stock based on the movements in the options market lately.
zacks.com
- 1 month ago
5 Ultra-High-Yield Dividend Stocks for 2025 Wall Street Is Pounding the Table On
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and offer a promising avenue for total return.
247wallst.com
- 1 month ago
Verizon Frontline powers NORAD Tracks Santa initiative for 22nd year
Enhanced network solutions and Verizon Frontline assets provide redundancy and reliability so children around the world can track Santa Enhanced network solutions and Verizon Frontline assets provide redundancy and reliability so children around the world can track Santa
globenewswire.com
- 1 month ago
New Strong Sell Stocks for November 19th
FRO, DHT and CVE have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2024.
zacks.com
- 1 month ago
Verizon Frontline Crisis Response Team supports 800+ agencies during 2024 emergency responses
What you need to know: The Verizon Frontline Crisis Response Team deployed nearly 900 times in 2024, supporting first responders in nearly every state and Washington D.C. The team responded to requests for support from public safety agencies during responses to tornadoes, hurricanes, and wildfires.
globenewswire.com
- 1 month ago
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual disease (MRD)-negative status (100% elimination of cancer cells). The results build on data from the prior trial, in which 100% of frontline patients also achieved remission.
accesswire.com
- 1 month ago
Spectral AI Incorporates Frontline Feedback into Improved Software Release for Enhanced Diagnostic Precision
DALLAS, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the completion of enhancements to its technical file to support significant software updates for its DeepView SnapShot® M and DeepView AI-Burn® system in the UK. These upgrades, informed by real-world experience and frontline feedback from clinicians, are designed to enhance product performance and usability in the UK, further solidifying the Company's commitment to delivering and commercializing cutting-edge solutions in critical care settings.
globenewswire.com
- 1 month ago
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML – – BEAT AML data highlight the potential for revumenib to advance the current standard of care – WALTHAM, Mass. , Dec. 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced additional positive data from the AUGMENT-101 trial of Revuforj® (revumenib) in relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) and the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed AML patients.
prnewswire.com
- 1 month ago
8. Profile
Summary
Frontline Ltd. FRO
COUNTRY
BM
INDUSTRY
Oil & Gas Midstream
MARKET CAP
$ 3.95 B
Dividend Yield
2.71%
Description
Frontline Ltd., a shipping company, engages in the seaborne transportation of crude oil and oil products worldwide. It owns and operates oil and product tankers. As of December 31, 2021, the company operated a fleet of 70 vessels. It is also involved in the charter, purchase, and sale of vessels. The company was founded in 1985 and is based in Hamilton, Bermuda.
Contact
Par-la-Ville Place, Hamilton, HM 08
https://www.frontline.bm
IPO
Date
Aug. 6, 2001
Employees
88
Officers
Marios Saveriades
Secretary
Mr. Lars H. Barstad
Chief Executive Officer of Frontline Management AS
Ms. Inger Marie Klemp
Chief Financial Officer of Frontline Management AS